Ronda L. Bloom, M.D.

North Shore Diabetes and Endocrine Associates 3003 New Hyde Park Rd, Suite 201 New Hyde Park, NY 11042 1/19/14

Phone 516-327-0850 rbloom@nsdea.com

July 2014

TRAINING

- property

New York University Medical Center New York, NY Fellow, Division of Endocrinology, July 2003–June 2005 Provided inpatient and outpatient care at NYU Hospital, Bellevue Hospital and the Manhattan VA Hospital. Experienced in treating a broad spectrum of endocrine diseases in a diverse patient population. Participated in diabetes research.

Mount Sinai Medical Center New York, NY Resident, Department of Medicine, July 1999-June 2002 Completed a three year program with responsibilities including initiating plans of care in the inpatient and outpatient settings as well as teaching junior house staff and medical students.

EDUCATION

Albert Einstein College of Medicine Bronx, NY Doctor of Medicine, June 1999

University of Pennsylvania Philadelphia PA Bachelor of Arts in Biology, cum laude, December 1994

EMPLOYMENT

Endocrinologist, North Shore Diabetes and Endocrine Associates 3003 New Hyde Park Rd., Suite 201, New Hyde Park, NY 11042 July 2011- present Partner and sub-investigator for research studies.

Endocrinologist, North Shore Diabetes and Endocrine Associates 3003 New Hyde Park Rd., Suite 201, New Hyde Park, NY 11042 July 2005- 2011 Staff endocrinologist and sub-investigator for research studies.

Primary Care Physician, **Yaffe, Ruden and Associates** New York, NY July 2002–June 2003

Physician of internal medicine responsible for primary care of patients and for supervision of care by physician assistants primarily in an outpatient setting.

Academic Tutor, Albert Einstein College of Medicine Bronx, NY

September 1996-July 1997

Tutored first year medical students in anatomy, histology and biochemistry.

Research Assistant, 3-D Pharmaceuticals Philadelphia, PA

January 1995-May 1995

Compiled and analyzed literature searches pertinent to company's various research projects.

LICENSURE/CERTIFICATION

New York State: License # 218242 – July 2000

Board Certified: American Board of Internal Medicine – 2002

Board Certified For Endocrinology -2005

PROFESSIONAL MEMBERSHIPS

American Diabetes Association- member since 2003

American Association of Clinical Endocrinologist- member since 2003

American Medical Association- member since 1996

American College of Physicians- associate member since 2003

HONORS AND AWARDS

Alpha Omega Alpha: Albert Einstein College of Medicine chapter, 1999

American Medical Women's Association Award: citation presented to women having graduated with academic distinction, 1999

Society of Penn Medical Scholars: honor society for undergraduate and graduate students of biological and medical sciences, 1991-1995

RESEARCH

Prevalence of gestational diabetes in HIV+ women in the WIHS population $\rm July~2003\text{--}2005$

Principal Investigator: Dr. Ann Danoff, New York University School of Medicine

The roles of insulin and LH in the development of hyper-testosteronism and virilism in post-menopausal women.

June 1998-August 1998

Preceptor: Dr. Ruth Freeman, Albert Einstein College of Medicine Bronx, NY

Comparing teenagers' knowledge of risk versus exposure to sexually transmitted diseases in urban middle schools

February 1994-April 1994

Preceptor: Catherine Tesar, PhD. Albert Einstein College of Medicine Bronx, NY

PUBLICATIONS

Bloom R, Greene L. Follicular Thyroid Carcinoma with Hyperfunctioning Metastases. Endocrine Trends. Baigelman W, Chodosh S, Beiser A, Pizzuto D, Janowski R. Sputum eosinophilia negates the need to perform sputum Gram's stain. Lung 1993; 171: 15-18.

LANGUAGES

Proficient in medical and conversational Spanish.

Research Studies

Subinvestigator - Inhaled insulin- MannKind (x3)

Subinvestigator - Inhaled insulin - Eli Lilly

Subinvestigator - Renal Insufficiency (x2) - Keryx Subinvestigator - Renal Insufficiency- Speedel

Subinvestigator - Oral Diabetic - Roche

Subinvestigator - Insulin + oral agent- Brigham and Women's Health Hospital

Subinvestigator - Diabetic Foot Ülcer- Apo Pharma

Subinvestigator - Oral Diabetic Agent- Merck

Subinvestigator - Oral Agent - NIH

Subinvestigator - Insulin (x2) Sanofi Aventis Subinvestigator - Hypertension - Novartis

Subinvestigator - Oral Diabetic Agent- Boehringer Ingelheim

Subinvestigator - Insulin/reduction of CRP - Brigham Women's Hospital

Subinvestigator - hyperlipidemia Agent- Pfizer Subinvestigator - Hypertensive Agent- Novartis Subinvestigator- Diabetes Prevention- Novartis

Subinvestigator - Reduction of CRP- Brigham Women's Hospital Subinvestigator- Growth Hormone- Lilly

Subinvestigator- Inhaled insulin (Pfizer x3)

Subinvestigator- Painful Neuropathy- Abbott Laboratories Subinvestigator- Injectable Diabetic medication-Amylin

Subinvestigator- Hypertension - Takeda

Subinvestigator- Oral Diabetic Agent- National Institute of Health

Subinvestigator- Oral Diabetic Agent-Novartis

Subinvestigator- Oral Agent- Nephropathy-Nephrogenex

Subinvestigator- Hypertension- Novartis

Subinvestigator- Injectable Diabetic medication- Novo Nordisk

Subinvestigator- Injectable Diabetic medication- Amylin Subinvestigator- Inhaled insulin (COPD)- MannKind

Sub investigator - Oral Diabetic agent- Johnson and Johnson

Sub investigator - Oral Diabetic Agent- Novartis Sub investigator - Oral Diabetic Agent-Akros

Sub Investigator- Inhaled Insulin (transfer study) MannKind

Sub Investigator- Oral Diabetic Agent- Forest (x2)

Sub Investigator- Diabetic Nephropathy-Fibrogen

Ronda Bloom Page 4 of 4

Sub Investigator- Inhaled insulin (device)-MannKind

Sub Investigator- Oral Diabetic Agent- AstraZeneca

Sub Investigator-Oral Diabetic Agent- Johnson & Johnson

Sub Investigator- Inhaled insulin (2 studies type I and Type II) Mannkind

Sub Investigator- Oral Diabetic Agent- Boehringer Ingelhiem

Sub Investigator- Oral Diabetic Agent/High Cardiovascular Risk- AstraZeneca

Sub Investigator- Insulin Delivery System-Valeritas

Sub Investigator- Insulin (2 studies, type I and II)

Sub Investigator- oral agent for Nephropathy- Abbott

Sub Investigator-Insulin for Type 1 Diabetics- Lilly

Sub Investigator-Insulin for Type 2 Diabetics- Lilly

Sub Investigator-Insulin for Type 1 Diabetics- Sanofi

Sub Investigator-Insulin for Type 2 Diabetics- Sanofi

Sub Investigator-Injectable Diabetic Medication- Sanofi

Sub Investigator-Injectable medication for Hyperlipidemia- Amgen

Sub Investigator-Oral Diabetic Agent- BristolMyers

Sub Investigator-infusible medication for insulin pump- Halozyme Theraputics

Sub Investigator-Diabetic Nephropathy-AbbVie

Sub Investigator- MACE assessment of an Oral Diabetic Agent- AstraZeneca

Sub Investigator-Injectable Diabetic Medication-Sanofi

Sub Investigator-Injectable Diabetic Medication- Sanofi